Novacyt Announces a Capital Increase of 784,736 Euros
Novacyt has announced the launch of a capital increase with preferential subscription rights for a maximum amount of 784,736 euros. This move follows the completion of the acquisition of Southern Cross Diagnostics.
Details of the Subscription Offer
The molecular diagnostics group will offer existing shareholders the opportunity to subscribe to new shares at a price of 0.40 euros per share, with one new share for every 36 existing shares held. The subscription period will run from March 6 to March 17, 2026. Novacyt has secured subscription commitments representing 77.2% of the total capital increase amount, primarily from the former owner of Southern Cross Diagnostics and board members. A minimum of 75% of the subscriptions is required for the completion of the operation.
Financial Implications and Strategic Context
The estimated net proceeds from the capital increase, after deducting expenses of approximately 205,000 euros, will enable the Company to strengthen its equity. This fundraising takes place in a context where Novacyt has a cash position of 22.0 million euros as of December 31, 2025, and continues its development in molecular diagnostics, particularly through the integration of Southern Cross Diagnostics. The preferential subscription rights will be negotiable on Euronext Growth® Paris from March 4 to March 13, 2026.
